OMALIZUMAB RIKE IN THERAPY OF GRAVE THERAPEUTICALLY RESISTENT ALLERGIC ASTHMA WITH INVOLVEMENT OF SMALL RESPIRATORY WAYS AND FIXED BRONCHIAL OBSTRUCTION. A LITERATURE REVIEW AND CLINICAL OBSERVATION
https://doi.org/10.21518/2079-701X-2017-18-39-43
Abstract
In allergic asthma IgE plays a fundamental role in the development and maintenance of chronic inflammation, leading to remodelling of the airways, reduced lung function, development of fixed bronchial obstruction and resistance to therapy. Authors present literature data and clinical observation of the effectiveness of omalizumab-drug anti-IgE therapy in severe therapyresistant allergic asthma with fixed airflow obstruction.
About the Authors
I. I. Vorzheva
Irkutsk State Medical Academy of Postgraduate Education – a branch of the Russian Medical Academy of Continuous
Professional Education of the Ministry of Health of RF
Russian Federation
Russian Federation
PhD in medicine
L. A. Khashkina
Irkutsk State Clinical Hospital No.10
Russian Federation
Russian Federation
References
1. Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA). Updated 2017 //http://www.ginasthma.org.
2. Chung KF, Wenzel SE, Brozek JL et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J, 2014, 43: 343-373.
3. Palomares O, Sanchez-Ramon S, Davila I et al. dIvergEnt: How IgE Axis Contributes to the Continuum of Allergic Asthma and Anti-IgE Therapies. Int. J. Mol. Sci., 2017, 18: 1328.
4. Samitas K, DelimpouraV, Zervas E, Gaga M. Anti-IgE treatment, airway inflammation and remodelling in severe allergic asthma: current knowledge and future perspectives. Eur Respir Rev, 2015, 24: 594–601.
5. Roth M, Zhong J, Zumkeller C et al. The role of IgE-receptors in IgE-dependent airway smooth muscle cell remodelling. PLoS ONE, 2013, 8: e56015.
6. Redhu NS, Shan L, Al-Subait D et al. IgE induces proliferation in human airway smooth muscle cells: Role of MAPK and STAT3 pathways. Allergy Asthma Clin. Immunol, 2013, 9: 41.
7. Черняк Б.А., Воржева И.И. Эозинофилы и аллергия. Российский Аллергологический Журнал, 2013, 4: 3-12.
8. Cottini M, Lombardi C, Micheletto C. Small airway dysfunction and bronchial asthma control: the state of the art. Asthma Research and Practice, 2015, 1: 13.
9. Российское респираторное общество, Педиатрическое респираторное общество. Клинические рекомендации по диагностике и лечению бронхиальной астмы 2016. http:// spulmo.ru/obrazovatelnye-resursy/federalnyeklinicheskie-rekomendatsii/
10. Княжеская Н.П., Белевский А.С., Осипова Г.Л., Фабрика М.П. Таргетная терапия бронхиальной астмы: в фокусе внимания омализумаб. Практическая пульмонология, 2015, 2: 32-38.
11. Abraham I, Alhossan A, Lee C S et al. ‘Real-life’ effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review. Allergy, 2016, 71: 593–610.
12. Riccio AM, Mauri P, De Ferrari L et al. Galectin-3: an early predictive biomarker of modulation of airway remodeling in patients with severe asthma treated with omalizumab for 36 months. Clin Transl Allergy, 2017, 7: 6.
13. Hoshino M, Ohtawa J. Effects of adding omalizumab, an anti-immunoglobulin E antibody, on airway wall thickening in asthma. Respiration, 2012, 83: 520–528.
14. Tajiri T, Niimi A, Matsumoto H et al. Comprehensive efficacy of omalizumab for severe refractory asthma: a time-series observational study. Ann Allergy Asthma Immunol, 2014, 113: 470-475.
15. Ильина Н.И., Намазова-Баранова Л.С., Емельянов А.В. и др. Алгоритм назначения иммунобиологических препаратов при тяжелой атопической бронхиальной астме в России (Согласительный документ). Российский Аллергологический Журнал, 2014, 4: 26-27.
Review
For citations:
Vorzheva II, Khashkina LA. OMALIZUMAB RIKE IN THERAPY OF GRAVE THERAPEUTICALLY RESISTENT ALLERGIC ASTHMA WITH INVOLVEMENT OF SMALL RESPIRATORY WAYS AND FIXED BRONCHIAL OBSTRUCTION. A LITERATURE REVIEW AND CLINICAL OBSERVATION. Meditsinskiy sovet = Medical Council. 2017;(18):39-43. (In Russ.) https://doi.org/10.21518/2079-701X-2017-18-39-43
Views:
618
Email this article 